Surgery
Volume 133, Issue 1 , Pages 40-48 , January 2003

Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases

,Accepted 19 July 2002.

References 

  1. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29
  2. Rougier P, Milan C, Lazorthes F, Fourtainier G, Partensky C, Baumel H, et al.  Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–1400
  3. Davis HL. Chemotherapy of large bowel cancer. Cancer. 1982;50:2638–2646
  4. Köhne-Wömpner CH. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol. 1992;19:105–125
  5. Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg. 1989;76:545–548
  6. Ackermann NB. The blood supply of experimental liver metastases: IV, changes in vascularity with increasing tumor growth. Surgery. 1974;75:569–589
  7. Kemeny NE. Regional chemotherapy of colorectal cancer. Eur J Cancer. 1995;31A:1271–1276
  8. Lorenz M, Müller HH, for the German Cooperative Group on Liver Metastases ALM . Randomized, multicenter trial of 5-fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with non-resectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18:243–254
  9. Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993;114:928–935
  10. Fordy C, Burke D, Earlam S, Twort P, Allen-Mersh TG. Treatment interruptions and complications with two continous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer. 1995;72:1023–1025
  11. Watkins E, Khazei AM, Nahra KS. Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet. 1970;130:581–605
  12. Rayner AA, Kerlan RK, Stagg RJ, Price DC, Hohn DC. Total hepatic arterial perfusion after occlusion of variant lobar vessels: implications for hepatic arterial chemotherapy. Surgery. 1986;99:708–714
  13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA. 1958;53:457–462
  14. Meta-analysis Group in Cancer . Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–258
  15. Schlag P, Hohenberger P, Hölting T, Buhl K, Schwarz V, Herfarth C. Hepatic arterial infusion (HAI) chemotherapy for liver metastases of colorectal cancer using 5-FU. Eur J Surg Oncol. 1990;16:99–104
  16. Metzger U, Weder W, Röthlin M, Largiader F. Phase II study of intra-arterial Fluorouracil and mitomycin C for liver metastases of colorectal cancer. Recent Results Cancer Res. 1991;121:198–204
  17. Sugihara K. Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study. Surgery. 1995;117:624–628
  18. Howell JD, McArdle CS, Kerr DJ, Buckles J, Ledermann JA, Taylor I, et al.  A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. Br J Cancer. 1997;76:1390–1393
  19. Cohen A, Kaufman S, Wood W, Greenfield A. Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg. 1983;145:529–533
  20. Niederhuber J, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984;53:1336–1343
  21. Hohn D, Rayner S, Economou J, Ignoffo R, Lewis B, Stagg R. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer. 1986;57:465–470
  22. Martin J, O'Connell M, Wieand H, Fitzgibbons R, Mailliard J, Rubin J, et al.  Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg. 1990;125:1022–1027
  23. Rougier P, Laplanche A, Huguier M, Hay J, Ollivier J, Escat J, et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–1118
  24. Allen-Mersh T, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  25. Kemeny N, Seiter K, Conti J, Cohen A, Bertino J, Sigurdson E, et al.  Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. Cancer. 1994;73:1134–1142
  26. Yoshikawa M, Ebara M, Nakano T, Minoyama A, Sugiura N, Ohto M. Percutaneous transaxillary catheter insertion for hepatic artery infusion chemotherapy. AJR Am J Roentgenol. 1992;158:885–886
  27. Sawada S, Fujiwara Y, Koyama T, Katsube Y, Kato T, Oshima T, et al.  Percutaneous transfemoral arterial infusion chemotherapy for metastatic liver tumors—placement of 3 Fr balloon catheters. Radiat Med. 1992;10:6–12
  28. Germer C, Boese-Landgraf J, Albrecht D, Wagner A, Wolf K, Buhr H. The fully implantable minimally invasive hepatic artery catheter for locoregional chemotherapy of nonresectable liver metastases in defective conventional therapy catheters. Chirurg. 1996;67:458–462
  29. Oi H, Kishimoto H, Matsushita M, Hori M, Nakamura H. Percutaneous implantation of hepatic artery infusion reservoir by sonographically guided left subclavian artery puncture. AJR Am J Roentgenol. 1996;166:821–822
  30. Hayashi N, Sakai T, Kitagawa M, Kimoto T, Ishii Y. Percutaneous long-term arterial access with implantable ports. Direct subclavian approach with US. Eur J Radiol. 1998;26:304–308
  31. Seki H, Kimura M, Yoshimura N, Yamamoto S, Ozaki T, Sakai K. Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery. Clin Radiol. 1999;54:221–227
  32. Wacker F, Boese-Landgraf J, Wagner A, Albrecht D, Wolf K, Fobbe F. Minimally invasive catheter implantation for regional chemotherapy of the liver: a new percutaneous transsubclavian approach. Cardiovasc Intervent Radiol. 1997;20:128–132
  33. Mosseri M, Fingert HJ, Varticousky L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase-C mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–3033
  34. Roth J, Wallner B, Safi F. Arterial perfusion abnormalities of the liver after hepatic arterial infusion chemotherapy and their correlation with changes in the metastases: evaluation with CT and angiography. AJR Am J Roentgenol. 1989;153:751–754
  35. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, et al.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamthasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327–334
  36. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al.  Upper extremity deep venous thrombosis in cancer patients with venous access device—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75:251–253
  37. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost. 1997;78:133–136

☆ Reprint requests: Matthias Lorenz, MD, Department of General and Vascular Surgery, University of Frankfurt Medical Center, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

☆☆ 0039-6060/2003/$30.00 + 0

PII: S0039-6060(02)21643-8

doi: 10.1067/msy.2003.37

Surgery
Volume 133, Issue 1 , Pages 40-48 , January 2003

Article Tools

* Image Usage & Resolution